However, the majority of NSCLC patients inevitably develop drug resistance to osimertinib over time, with the reported possible mechanisms predominantly involving EGFR-dependent (e.g., C797X mutation)[6] and EGFR-independent pathways, including bypass activation, downstream signaling pathway activation, epithelial-mesenchymal transition (EMT), and small-cell transformation[5,7]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.